Replication-competent adenoviral vectors hold the promise to be more efficient gene delivery vehicles than their replicationdeficient counterparts, but they are also associated with a higher risk for adverse effects, especially in light of the fact that there is no established effective therapy for serious, disseminated adenovirus infection. To assess whether the therapeutic options to inhibit adenoviral replication can be enhanced by expressing a suicide gene, we examined the antiadenoviral effects of 15 drugs against wild-type adenovirus type 5 (Ad5) and an Ad5-based replication-competent vector expressing herpes simplex virus-1 thymidine kinase (HSV-tk) (Ad.OW34) using a real-time polymerase chain reaction -based assay and flow cytometry. Ad5 and Ad.OW34 were highly susceptible to the fluorinated pyrimidine analogs 5-fluoro-2 0 -deoxyuridine (FUdR), 5-fluorouridine (FUR), and trifluorothymidine (TFT), with a mean 50% inhibitory concentration (IC 50 ) ranging from 0.12 to 0.32 mM. The mean IC 50 of ribavirin and cidofovir (CDV) for Ad5, the most frequently used drugs to treat adenovirus disease, was 6.87 and 3.19 mM, respectively. In contrast to Ad5, the Ad.OW34 vector was susceptible to (E)-5-(2-bromovinyl)-2 0 -deoxyuridine (BVdU, IC 50 0.09 mM), ganciclovir (GCV, IC 50 0.19 mM), and acyclovir (ACV, IC 50 32.04 mM). Additionally, we demonstrated in an animal model that Ad.OW34 vector replication can be inhibited significantly by GCV, CDV, and TFT by 35.2, 7.7, and 3.7-fold, respectively, compared to untreated animals. The observed antiadenoviral effects were primarily not through cell killing, since the in vitro 50% cytotoxic concentrations (CC 50 ) were more than 1000 times higher than the antiadenoviral IC 50 of the drugs examined, even in cells stably expressing HSV-tk. Since for HSV-tk-dependent inhibition of adenoviral vectors, stability of HSV-tk expression is crucial, we examined Ad.OW34 vector stability, by passaging the vector 10 times serially in the presence of 10 mM GCV. The HSV-tk/GCV system neither changed the susceptibility of Ad.OW34 to GCV significantly nor detectable vector rearrangements occurred, suggesting that the system might be suitable as a fail-safe mechanism to stop adenoviral vector replication.
U ntil recently, for safety, crippled, replication-defective viruses have been used as vectors for cancer gene therapy. Consequently, most clinical trials have shown minimal gene transfer at best and few tumor responses. [1] [2] [3] Even if at first only a small fraction of tumor cells has been infected, replication-competent vectors have the potential to overcome poor transduction efficiency since vector replication leads to in situ amplification of the viral inoculum and spread throughout the tumor by subsequent cycles of infection and lysis of neighboring tumor cells. First controlled clinical trials with an oncolytic adenovirus in combination with chemotherapy have shown encouraging antineoplastic activity. 44 However, due to their ability to replicate and spread from the initial site of infection, replication-competent vectors are also associated with a higher risk for adverse effects than their replication-deficient counterparts.
For safety and improved therapeutic index of replication-competent adenoviral vectors, it has been attempted to restrict vector replication to tumors. In contrast to initial findings by Bischoff et al, 5 deletion of the adenovirus E1B-55 K gene does not restrict virus replication to p53-dysfunctional cells. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Other approaches involved the transcriptional targeting of adenovirus E1A genes, which are pivotal for adenoviral replication. [17] [18] [19] However, targeting of vector replication by this approach might be poor for two reasons. First, promoter fidelity might be abolished by the upstream adenoviral packaging sequence that contains two enhancer elements of the E1A promoter, which are active in most cell types tested and essential for adenoviral encapsidation. [20] [21] [22] [23] Second, already small amounts of E1A gene products are sufficient to initiate adenoviral replication. 24 In addition, E1A inframe deletion mutants have been reported that support viral growth in tumor cells but not in normal cells. 25 However, in vivo verification of these adenoviral vectors' tumor specificity is hampered by the lack of a permissive non-human host since human adenoviruses replicate only in human cells.
Since their initial description in the 1950's, adenoviruses have been known as a cause of common childhood respiratory illnesses. [26] [27] [28] In immunocompetent patients, most of these infections are asymptomatic, mild, or selflimited. In the immunocompromised host, however, adenovirus infections can cause severe localized disease including pneumonitis, colitis, hemorrhagic cystitis, hepatitis, nephritis, encephalitis, or disseminated disease with multiorgan failure. [29] [30] [31] [32] Disseminated adenovirus disease has been reported in patients with AIDS or malignancies 29, [33] [34] [35] and in bone marrow or solid organ transplant recipients 32, [36] [37] [38] [39] with increasing frequency. The overall incidence of adenoviral disease in immunocompromised patients ranges from 10 to 20%. 29, 31, 37, 40 Case fatality rates as high as 50-80% have been described. 29, 32, 40, 41 So far, experience is greatest with parenteral administration of the broad-spectrum antiviral ribonucleoside ribavirin (RBV), 41 which has documented activity against adenovirus in vitro. 42 In some cases therapy was successful, [43] [44] [45] [46] [47] [48] but many patients died despite RBV treatment. [49] [50] [51] [52] [53] [54] [55] [56] Furthermore, cidofovir (CDV), an acyclic nucleoside phosphonate that has activity against virtually all DNA viruses including adenovirus, 57, 58 has been evaluated for disseminated adenovirus disease with limited success. [59] [60] [61] Reports of successful alternative strategies are less common and include an apparent beneficial effect of donor leukocyte infusion, 53, 54 intravenous immunoglobulin, 62 and ganciclovir(GCV) treatment. 63, 64 In light of the limited and nonspecific therapeutic options for the treatment of wild-type adenovirus infections 65 and recent concerns about adenovirus-mediated gene transfer, 66, 67 we examined whether the therapeutic options to inhibit adenoviral replication can be enhanced by expressing herpes simplex virus-1 thymidine kinase (HSV-tk). Hence, we analyzed the antiviral activity of 15 potential antiviral drugs against a wild-type human adenovirus serotype 5 (Ad5)-based replication-competent vector expressing HSV-tk (Ad.OW34). To evaluate the effects attributable to the expression of HSV-tk, we also examined the effects of the drugs on wild-type Ad5 replication, using a quantitative polymerase chain reaction (qPCR)-based assay. Furthermore, we determined cytotoxicity of the drugs in vitro and in vivo in order to assess whether the observed antiadenoviral effects are just due to cell killing.
Among the evaluated substances were 10 pyrimidine nucleoside analogs, which encompass a diverse group of drugs that have been employed in the treatment of diverse afflictions, including neoplastic diseases, psoriasis, infections caused by fungi and viruses, including the antiherpes drugs (E)-5-(2-bromovinyl)-2 0 -deoxyuridine (BVdU), trifluorothymidine (TFT), and pyrimidine dideoxynucleoside analogs, inhibitors of HIV reverse transcriptase inhibitors. Also, we determined the antiviral effects of the acyclic nucleoside analogs acyclovir (ACV) and GCV that are used for the therapy of herpesvirus infections. We also examined the antiadenoviral effects of foscarnet (PFA), a clinically used pyrophosphate analog that inhibits not only all human herpesviruses but also HIV. Furthermore, we analyzed the effects of RBV, a nucleoside analog of guanosine shown to be active against a broad spectrum of DNA and RNA viruses, and the acyclic nucleoside phosphonate CDV that has activity against virtually all DNA viruses.
In addition, we analyzed the Ad.OW34 vector for stability of HSV-tk expression and examined in vivo the effects of GCV, CDV, and TFT on Ad.OW34 vector replication.
Results
A qPCR-based assay was established to examine the effects of 15 potential antiviral compounds (structural formulae shown in Fig 1) on the replication of wild-type Ad5 and Ad. OW34 vector, an Ad5-based (E1 + , nE3) replication-competent virus expressing HSV-tk (genetic structures of the vectors used in this study are shown in Fig 2) .
In vitro antiviral potency of drugs
The in vitro antiviral activity of the evaluated drugs is summarized in Table 1 . Their potency was not significantly influenced whether HeLa, Panc-1, or A375 cells were used for the assay. The following data were obtained in at least three independent experiments on HeLa cells. The most effective inhibitors of Ad5 replication were the fluorinated pyrimidine nucleoside analogs 5-fluoro-2 0 -deoxyuridine (FUdR) with an inhibitory concentration 50% (IC 50 ) of 0.1370.06 mM, 5-fluorouridine (FUR) with IC 50 of 0.2070.09 mM, and TFT with IC 50 of 0.3270.08 mM. Inhibition of adenoviral replication by TFT was significantly different compared to FUdR or FUR (Po.05), whereas there was no significant difference between FUdR and FUR (P4.05).
The IC 50 of CDV and RBV were 3.1971.03 and 6.8771.89 mM, respectively. In our in vitro assay, the antiadenoviral efficacy of CDV was significantly greater than that of RBV (Pr.03). However, FUdR, FUR, and TFT were more potent than CDV (Po.001). In addition, 3 0 -deoxy-3 0 -fluorothymidine (FLT) had an effect on Ad5 replication with an IC 50 of 3.6570.71 mM.
All drugs with antiadenoviral activity inhibited the replication of the HSV-tk-expressing Ad.OW34 vector to the same extent as wild-type Ad5. However, the antiherpes drugs BVdU, GCV, and ACV inhibited Ad.OW34 vector replication strongly, but not Ad.5 replication in concentrations up to 100 mM. The IC 50 
-dihydrothymidine (DHT), and PFA had no effect on the replication of either Ad5 or Ad.OW34 vector in concentrations up to 100 mM.
In vitro cytotoxicity of antiviral compounds
To determine whether the observed in vitro antiadenoviral effects of the compounds are due to inhibition of viral DNA replication or due to cytotoxic effects, melanoma cells stably expressing HSV-tk (A375 STK) were incubated with test compounds for 36 hours at 371C. The 50% cytotoxic concentrations (CC 50 ) were determined with the CellTiter-Glot Luminescent Cell Viability Assay (Promega, Madison, WI). The rank order of the cytotoxicity of the compounds was TFT4FUdR, FUR4RBV4GCV4BVdU, FLT4ACV4CDV with a CC 50 ranging from 2 to 20 mM, more than 1000-fold above the IC 50 .
Flow cytometric analysis of selected compounds on adenoviral replication
To determine whether the observed in vitro antiadenoviral effects of the compounds are not only due to inhibition of Figure 1 Chemical structures of drugs evaluated in this study. 
Experiments have been performed at least three times and data presented as mean inhibitory concentration 50% (IC 50 ) or 90% (IC 90 )7SEM. There was no detectable adenoviral DNA in the liver, even of animals that received no antiadenoviral treatment (detection level 10 Ad5 copies per mg genomic DNA).
In vivo tumor apoptosis detection
To determine whether the observed in vivo antiadenoviral effects of the compounds are due to inhibition of viral DNA replication or due to cytotoxic effects, animals bearing A375 STK tumors were treated with GCV, CDV, or TFT (25 mg/kg i.p. b.i.d. for 3 days). As a control, one group of animals received GCV (150 mg/kg i.p. b.i.d. for 3 days) at doses used for cytoreductive suicide gene therapy. As shown in Figure 5 , animals that received test compounds at doses used for antiviral therapy in this study showed only a slight increase of Annexin V expression. In addition, antiviral treatment did not significantly increase the number of propidium iodinepositive cells, showing dead cells, when compared to untreated cells (data not shown). However, at higher dose levels of GCV, Annexin V expression of A375 STK tumor cells was increased.
In vitro Ad.OW34 vector stability
To examine Ad.OW34 vector stability and functional HSV-tk expression, the vector was passaged serially 10 times in HeLa cells without GCV and in the presence of 10 mM GCV. As shown in Figure 6 , gel electrophoretic separation of vector DNA after the first and 10th passage with and without GCV digested with the restriction u n t r e a t e d In addition, GCV-sensitivity of Ad.OW34 vector did not change significantly after 10 serial passages in HeLa cells in the absence and presence of 10 mM GCV when compared side-by-side to parental Ad.OW34 vector by qPCR-based antiviral assay (data not shown). Furthermore, sequence analysis of the HSV-tk gene of four vector clones did not reveal mutations (data not shown).
Discussion
We and others combined viral oncolysis with prodrug suicide gene therapy in an attempt to enhance the overall antineoplastic efficacy of virotherapy. The intrinsic oncolytic effects of E1B-55K-deleted adenoviruses could be significantly enhanced in several solid xenograft tumor models when prodrug (GCV alone or in combination with 5-fluorocytosine (5-FC)) was withheld until maximum vector replication and gene expression occurred. [68] [69] [70] However, GCV administration was not beneficial to the intrinsic oncolytic activity of an adenovirus (Ad.OW34) with a much more robust replication than the E1B-55K-deleted vector Ad.TK RC , expressing the entire adenovirus E1 region as well as HSV-tk under conditions that favor active viral replication and spread, 14 probably because the potential HSV-tk/GCV-mediated enhancement of the intrinsic viral oncolytic activity was balanced out by the virostatic effects of GCV.
Since apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports, we examined in this study HSV-tk-dependent andindependent inhibition of a replication-competent adenoviral vector by a panel of 15 potential antiviral compounds to determine whether the therapeutic options to inhibit adenoviral replication could be enhanced by the expression of a suicide gene.
To screen antiadenoviral agents, previous studies used either plaque reduction, fluorescent focus reduction assays, 59, 60, 71 or MTT-based cytotoxicity assay. 58, 72 We developed a real-time qPCR-based assay to determine the effects of the examined drugs on the adenoviral replication in vitro and in vivo. The advantages of qPCR are rapid testing time, broad dynamic range, high specificity, accuracy, and high sensitivity allowing the detection of moderate drug effects in vitro and in vivo. Furthermore, this assay allows the analysis of drug effects on a single viral replication cycle. Despite DNA concentrations not necessarily correlating with viable virus, similar IC 50 values have been obtained for Ad.OW34 by plaque reduction assay and qPCR technique. 14 In addition to the qPCR-based technique, we analyzed by flow cytometry the antiadenoviral effects of selected drugs on the spread of the GFP-expressing Ad.OW94 vector. Since HSV-tk/GCV-mediated cytotoxic effects are independent of the HSV-tk expression level, 73 we used a stable HSV-tk-expressing A375 melanoma cell line (A375 STK) to assess the HSV-tk dependent drug effects. As the mean fluorescence intensity as well as the percentage of GFP-positive cells decreased when compared to untreated cells, we were able to demonstrate, that not only the viral replication as demonstrated by qPCR but also the spread of the vector was inhibited by the drugs tested.
In contrast to previous studies, we also analyzed the antiadenoviral effect of GCV, CDV, and TFT on Ad.OW34 vector replication in vivo. Because injection of a replication-defective adenovirus expressing GFP in established subcutaneous A375 tumor resulted in a tumor transduction of 3.1, 4.8, 7.6, 7.4, and 13.5%, we mixed Ad.OW34-infected and uninfected cells that are subsequently injected into animals to eliminate unpredictable tumor transduction as an additional variable in the determination of the antiadenoviral drug effect in vivo. We are aware that this model does not represent the clinical setting; however, the main objective of this study was to determine HSV-tk-dependent andindependent inhibition of adenoviral replication by a panel of drugs.
A further limitation of our model is due to the adenoviral host-specificity and the lack of a permissive animal model for human adenoviruses. Consequently, vector replication and spread is restricted to the human xenograft. As we were not able to detect vector sequences in the liver by qPCR, even of untreated animals, we were not able to demonstrate in vivo inhibition of viral spread to other organs by the compounds tested.
In our study, agents effective against wild-type Ad5 were nucleoside analogs that did not need to be phosphorylated by viral enzymes to exert their antiviral effects. Their antiviral activity was independent of the cell lines tested and inhibited wild-type Ad5 and Ad.OW34 vector replication to the same degree. The following six compounds had activity against wild-type Ad5 replication of which only the first two drugs are approved for systemic intravenous administration in humans. RBV demonstrated a moderate antiadenoviral effect, confirming previous reports. 42 The high calculated IC 90 of B250 mM might explain the fact that reported clearance of adenovirus infection occurred most frequently in patients with adenovirus-associated hemorrhagic cystitis due to high bladder concentrations of RBV. 43, 44, 53, 74, 75 Intravenous RBV administration is associated with anemia due to intravascular hemolysis and bone marrow-suppressive effects. 76 The antiadenoviral effects of CDV, which is approved for the treatment of CMV retinitis in AIDS patients, have been described previously for several serotypes including Ad5. 60, 61, 77, 78 However, the IC 50 value in our system was about 10 times lower than previously reported. 78 The major adverse effect observed thus far for CDV is nephrotoxicity. 79 In the clinical setting, the very long intracellular half-life (448 hours) of CDV metabolites is advantageous since it allows infrequent dosing (i.e. every week or every 2 weeks). 77 With the exception of the investigational HIV-1 reverse transcriptase inhibitor FLT, which had moderate anti- 82, 83 The third substance in this group, TFT, is approved in the United States for the topical treatment of epithelial keratitis caused by HSV-1 and -2. TFT has been reported to have in vitro activity against some strains of adenovirus (13, 19 , and weakly 8). 71 In our in vitro assay, the effects of the three fluorinated pyrimidine analogs on Ad5 replication were significantly greater than that of RBV or CDV. Although the in vitro antiviral activity of TFT was similar to that of GCV, it was less effective in vivo than CDV, probably due to rapid metabolic degradation in the liver.
To elucidate whether the adenoviral replication could be inhibited more effectively by an HSV-tk-dependent mechanism, we evaluated ACV, GCV, and BVdU for their effects on the replication of Ad.OW34 vector. In contrast to the other examined compounds, the antiviral activity and selectivity of these drugs is based on their specific activation by herpesvirus-encoded kinases, that convert these nucleoside analogs into their monophosphate metabolites and BVdU in its mono-and diphosphate form. 84 The drugs are then phosphorylated to their triphosphate form by cellular kinases, which are competitive inhibitors of the viral DNA polymerase. In addition, incorporation of these nucleoside analogs into DNA during elongation leads to premature DNA chain termination. 85 As the drugs are specifically activated by viral thymidine kinases, none of the drugs had an effect on the replication of Ad5 at the concentrations tested, confirming the high specificity for HSV-1 thymidine kinase.
In this study, we were able to demonstrate directly that GCV is a strong inhibitor of Ad.OW34 vector replication not only in vitro but also in vivo. These results also explain why the time point when GCV is given after intratumoral injection of the replication-competent vector expressing HSV-tk is crucial for its oncolytic effect. 70 In vitro and in vivo the effect of GCV on Ad.OW34 vector replication was significantly greater than that of CDV. The in vitro effect of ACV on Ad.OW34 vector replication was more than 100-fold lower compared to GCV.
Furthermore, Ad.OW34 vector replication was highly susceptible to BVdU. However, there was no statistically significant difference in the antiviral activity when compared to GCV. In contrast to DHT, which had no antiadenoviral activity, BVdU has a 2(E)-bromovinyl entity that is crucial for the selective activity against HSV-1 and VZV. 86 BVdU is currently licensed only in Germany for VZV therapy. 87 In contrast to ACV and GCV, BVdU has a good oral bioavailability.
The observed antiadenoviral effects were primarily not through cell killing, since the in vitro CC 50 were more than 1000 times higher than the antiadenoviral IC 50 of the drugs examined, even in cells stably expressing HSV-tk. Furthermore, there was only a slight increased apoptosis detectable in the in vivo studies.
Virus replication was considerably more affected than that of cells, most likely since the activated drugs exert their toxicity only in the S-phase and the replication-cycle of viruses is much shorter than that of cells. Furthermore, the tumor-suppressor p53 allows cells that have DNA damage to arrest in the G1-phase of the cell cycle, permitting repair. If DNA repair is inadequate, p53 can elicit programmed cell death through apoptosis.
In order to achieve cytoreductive effects using the HSVtk/GCV system, much higher dose levels are required than for obtaining antiviral effects. In order to enhance the antitumor efficacy of the HSV-tk/GCV system, we are currently conducting a phase I study of intralesional administration of an HSV-tk expressing adenovirus vector in combination with escalating doses of GCV in patients with cutaneous metastatic malignant melanoma. 88 Taken together, the highest effects on Ad5 replication of the drugs tested that exerted their antiviral effects independent of viral thymidine kinase was seen with the fluorinated pyrimidine analogs FUdR, FUR, and TFT. However, due to their mode of action, these drugs are highly toxic in humans with a narrow margin of safety. Of the drugs tested that did not require viral activation, the highest specific antiviral activity was seen with CDV. However, inhibition of Ad.OW34 vector replication was significantly greater with GCV and BVdU, both requiring specific activation by herpesvirus-encoded kinases. As, currently, specific treatment options for severe adenovirus disease are limited by the lack of an established effective therapy, the incorporation of a fail-safe mechanism, like the HSV-tk/GCV or cytosine deaminase/5-FC (which converts the relatively nontoxic antifungal agent 5-FC into 5-FU) system, to stop adenoviral vector replication might be warranted, also in light of the fact that CDVresistant Ad5 isolates have been isolated in vitro.
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Materials and methods
Cell lines and drugs
The human cervix carcinoma cell line HeLa (CCL-2) and the human melanoma cell line A375 (CRL-1619) were purchased from the American Type Culture Collection (Manassas, VA). The human pancreatic cancer cell line Panc-1 (CRL-1469) was provided by Irmgard SchwarteWaldhoff (Knappschaftskrankenhaus, Bochum, Germany). The human embryonic kidney cell line 293 89 was obtained from Microbix Biosystems, Inc. (Toronto, Ontario, Canada). A375 STK 90 were generated by transduction of the parental cell lines with supernatant from PA317-STK cells 20 and subsequent G418 (Invitrogen/Gibco, Karlsruhe, Germany, 1 mg/ml for 3 weeks) selection followed by subcloning. Cell lines were propagated in D-10, consisting of Dulbecco's modified Eagle Inhibition of adenovirus vector replication O Wildner et al medium (DMEM) with high glucose, supplemented with 10% heat-inactivated fetal bovine serum and 50 mg/ml gentamycin. Tissue culture medium and supplements were purchased from Invitrogen/Gibco (Karlsruhe, Germany). Cells were maintained in the logarithmic phase of growth at 371C in a humidified atmosphere of 95% air and 5% CO 2 .
CDV was kindly provided by Norbert W Bischofberger, Gilead Sciences (Foster City, CA). GCV was purchased from F Hoffmann-La Roche (GrenzachWyhlen, Germany). ACV, RBV, TFT, FUdR, FUR, FLT, BVdU, AzdU, AZT, F-ddU, ddU, DHT, phosphonoformic acid (foscarnet, PFA) were purchased from Sigma-Aldrich (Munich, Germany).
Construction and production of adenoviral vectors
The Ad.OW34 and Ad.GFP vectors used in this study are described in detail elsewhere. 14, 15 Briefly, beginning with a first-generation adenovirus early region 1 (E1)-and adenovirus early region 3 (E3)-deleted adenoviral vector, we generated the replication-competent adenoviral vector Ad.OW34, which harbors in the E1 region an HSV-tk-IRES 91,92 -Ad5 E1 expression cassette driven by the human cytomegalovirus immediate-early (CMV-IE) promoter flanked upstream by the Ad5 packaging sequence and downstream by the Ad5 pIX. Ad.OW34 was generated by homologous recombination of pAd.CMV-TK E1 and pBHG10 93 in 293 cells, as described previously. 94 The replication-competent adenoviral reporter gene vector Ad.OW94 was generated by substituting the HSV-tk gene of the Ad.OW34 vector with the cDNA encoding enhanced GFP from the plasmid pGreenLantern-1 (Life Technologies, Grand Island, NY). In the replication-deficient adenoviral vector Ad.GFP, the E1 region was replaced by an expression cassette consisting of GFP (pGreenLantern-1, Life Technologies), driven by the human CMV-IE promoter in parallel to the transcriptional orientation of the adenovirus E1 gene products, and terminated by the bovine growth hormone polyadenylation site. The reference strain VR-5 (ATCC, Manassas, VA) was used as wild-type adenovirus type 5 (Ad5).
The replication-competent viruses Ad.OW34 Ad.OW94, and Ad5 were propagated in HeLa cells; the replication-defective Ad.GFP vector was amplified in 293 cells. All viruses were purified by two rounds of CsCl density centrifugation, 94 dialyzed (Slide-A-Lyzer, Pierce, Rockford, IL) against 1500 ml of PBS with 1 mM MgCl 2 and 10% glycerol four times (1 hour each) at 41C, and stored at À801C until use. The concentrations of all viruses were determined by measuring absorbency at 260 nm, 95 and the infectious titer was determined by plaque assay on 293 cells. 96 In all preparations, the ratio of infectious to noninfectious virus particles was approximately 1:80. The Ad.OW34 virus preparation was functionally characterized for HSV-tk expression by 
Adenovirus qPCR assay
A set of TaqMan PCR primers and probe 97 were designed to quantitate vector sequences using the Beacon Designer software (version 2; PREMIER Biosoft, Palo Alto, CA). In our assay, we used a probe 5 0 -(FAM)ACCTCTGAT-TAAACATGGCGCCATCC(TAMRA)-3 0 that annealed within the Ad5 E4orf6 region, flanked by the upstream 5 0 -GTAATTCACCACCTCCCGGTA-3 0 and downstream 5 0 -GGCTCTCCACTGTCATTGTTC-3 0 primers. The fluorescence intensity in each PCR capillary throughout the entire amplification procedure was monitored using a Light Cycler II (Roche Diagnostics, Mannheim, Germany).
The dynamic linearity of the assay was in the range of 5.10 1 to 6.10 6 copies of adenoviral DNA. The coefficient of variation for the qPCR, determined as the standard deviation divided by the mean slopes of the standard curves times 100, was found to be 1.8%. The detection level was determined to be 10 adenovirus DNA copies per mg of human genomic DNA.
qPCR-based anti-adenoviral assay
HeLa, Panc-1, and A375 cells were used for evaluation of antiadenoviral compound efficacy against wild-type Ad5 and Ad.OW34 vector. Cells were seeded at a density of 10 5 cells/well in six-well plates. After 12 hours, serial 10-fold dilutions of each antiviral agent, ranging from 0.01 to 100 mM, were prepared in D-10 culture medium with added Ad5 or Ad.OW34 vector resulting in an MOI of 5. Culture medium from the subconfluent cell monolayers was replaced with drug dilutions plus virus. The last well of each six-well plate was incubated only with virus and served as an untreated control. After 36 hours, cells were harvested with cell scrapers and centrifuged. After decantation of the culture medium, cells were snap-frozen and stored at À801C until DNA extraction using the DNeasy 96 Tissue Kit (QIAGEN, Hilden, Germany). Virus DNA copies were normalized to genomic DNA concentration. The 50 and 90% antiviral inhibitory dose (IC 50 and IC 90 , respectively) was defined as the concentration that achieved 50 or 90% inhibition of adenoviral replication in the qPCR assay, respectively.
Adenovirus vector stability assay
A confluent HeLa cell monolayer was inoculated with Ad.OW34 vector at a MOI of 0.1. After adsorption for 2-3 hours at 371C in a 5% carbon dioxide-water vapor atmosphere, the inoculum was aspirated and the cells were washed with PBS and replenished with medium containing 10 mM GCV. At appropriate time intervals, the cells were examined for progressive viral cytopathic effect (CPE). Medium and cells were collected at peak CPE (B8 day post infection) and stored at À701C until required for either further passage, or determination of the IC 50 . After 10 times serial passage, GCV sensitivity of passaged vector and parental stock Ad.OW34 vector were determined side-by-side in the qPCR-based antiviral assay. 88 After 12 hours, cells were harvested and extensively washed. Afterwards, infected cells were mixed at a ratio of 1:1 Â 10 4 with uninfected A375 cells. A total of 50 million viable A375 cells in 100 ml of serum-free DMEM with 10% Matrigel (Becton Dickinson, Heidelberg, Germany) were injected subcutaneously into the right flank of a nude mouse. For determination of drug-mediated in vivo cytotoxicity, nude mice received in the same manner 5 Â 10 7 A375 STK cells subcutaneously into the right flank. The animals were randomly assigned to treatment groups. Five animals were left untreated and nine animals each received intraperitoneal administration of GCV, CDV, or TFT (25 mg/kg) in 1 ml of saline twice daily for 3 consecutive days beginning 24 hours after tumor cell injection.
For collection of tumor and liver samples, animals were euthanized with CO 2 and specimens were harvested immediately with separate sets of sterile, DNA-free instruments. All samples were snap-frozen at the time of collection and stored in cryotubes at À801C until analysis. The total cellular DNA was isolated from about 30-40 mg tissue with the DNeasy 96 Tissue Kit (QIAGEN, Hilden, Germany).
In vitro cytotoxicity assay
We examined the compounds for cytotoxic effects with the CellTiter-Glot Luminescent Cell Viability Assay (Promega, Madison, WI) according to the manufacturer's instructions. This assay determines the number of viable cells in culture based on quantitation of ATP, which indicates the presence of metabolically active cells. ATP-based cell viability assays are more sensitive than other methods. 98, 99 A375 cells were seeded into 96-well tissue culture plates at a density of 10 4 cells/well. 24 hours later, cells in logarithmic phase of growth were incubated with a two-fold dilution series of the test compounds, ranging in concentration from 10 mM to 4.8 mM for 36 hours at 371C.
In vivo cytotoxicity assay
To determine whether in vivo antiviral effects of the test compounds are due to cytotoxic effects, two animals each bearing subcutaneous A375 STK tumors received twice daily 25 mg/kg or for control purpose 150 mg/kg GCV. Other treatment groups received twice daily 25 mg/kg CDV or TFT for 3 days consecutively. At the end of the treatment period, animals were euthanized and tumors were removed without overlying skin. Tumors were enzymatically digested with collagenase, hyaluronidase, and deoxyribonuclease as described previously. 100 For apoptosis and dead cell detection, Annexin V-FITC staining (Annexin V-FITC apoptosis detection kit I, BD Biosciences, Heidelberg, Germany) in conjunction with the vital dye propidium iodine and subsequent flow cytometric analysis has been used according to the manufacturer's instructions.
Flow cytometric analysis of GFP expression
To visualize the antiviral effects of GCV, RBV, CDV, TFT, and BVdU on adenoviral replication, subconfluent monolayers of A375 STK cells were infected at an MOI of 5 with the replication-competent GFP-expressing vector Ad.OW94 in the presence and absence of 25 mM test compounds. As a control, cells were also transduced with a replication-defective adenoviral vector carrying GFP. 101 After 72 hours, 2 Â 10 4 viable cells impermeable to propidium iodine were acquired and analyzed with a FACSCalibur flow cytometer (BD Biosciences Immunocytometry Systems, San Jose, CA).
Analytical and statistical methods
The curve fitting software TableCurve 2D version 4 (SPSS Inc., Chicago, IL) was used for calculation of IC 50 and IC 90 , respectively. After logarithmic data transformation, one-way analysis of variance with multiple comparison procedure (Tukey's test) was employed to compare treatments for significant differences, using the software STATISTICA 5.5 for Windows (StatSoft, Tulsa, OK). Data are presented throughout this study as mean7SEM.
Abbreviations E1, E3, Adenovirus early region 1 and 3, Respectively; CMV-IE, Cytomegalovirus immediate-early; HSV-tk, Herpes simplex virus-1 thymidine kinase; GFP, Green fluorescent protein; Ad5, Wild-type human adenovirus serotype 5; MOI, multiplicity of infection; PFU, plaque forming unit; qPCR, quantitative polymerase chain reaction.
